Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 5Breast Neoplasms 5Stomach Neoplasms 3Neoplasms 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Biliary Tract Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Muscle Invasive Bladder Cancer (MIBC) 1Hemangiosarcoma 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1

Interventions

Gemcitabine 45Cisplatin 34Oxaliplatin 23Capecitabine 17Fluorouracil 13Leucovorin 12pembrolizumab 11lenvatinib 11durvalumab 10S 1 (combination) 10Irinotecan 10Bevacizumab 9apatinib 7Nivolumab 7tremelimumab 6Trastuzumab 5envafolimab 4atezolizumab 4Injections 4Docetaxel 4trametinib 3titanium silicide 3tislelizumab 3irinotecan sucrosofate 3camrelizumab 3Radiotherapy 3Drug Therapy 3zanidatamab 2toripalimab 2surufatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Biliary Tract Neoplasms × zanidatamab × Clear all
NCT04466891 2025-09-15

HERIZON-BTC-01

Jazz Pharmaceuticals

Phase 2 Completed
87 enrolled 25 charts 1 FDA
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms

NCT03929666 2025-09-12

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Jazz Pharmaceuticals

Phase 2 Completed
74 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡